WO2001078744A1 - Produits composes a usage medical renfermant du formoterol et de la mometasone - Google Patents
Produits composes a usage medical renfermant du formoterol et de la mometasone Download PDFInfo
- Publication number
- WO2001078744A1 WO2001078744A1 PCT/GB2001/001648 GB0101648W WO0178744A1 WO 2001078744 A1 WO2001078744 A1 WO 2001078744A1 GB 0101648 W GB0101648 W GB 0101648W WO 0178744 A1 WO0178744 A1 WO 0178744A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical formulation
- formoterol
- pharmaceutically acceptable
- formulation according
- mometasone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- the present invention is concerned with combinations of formoterol and mometasone, particularly compositions containing a combination of formoterol and mometasone and the use of such compositions in medicine, particularly in the prophylaxis and treatment of respiratory diseases.
- Formoterol i.e. 2'-hydroxy-5'-[(RS)-1 -hydroxy-2 ⁇ [(RS)-p-methoxy- ⁇ - methylphenethyl]amino ⁇ ethyl]formanilide, particularly its fumarate salt is a well- known adrenoreceptor agonist which is now used clinically in the treatment of bronchial asthma and related disorders.
- EP 57,401 and US 4,472,393 describe mometasone i.e. 9,21-dichloro-11 ⁇ ,17- dihydroxy-16 ⁇ -methylpregna-1 ,4-diene-3,20-dione, esters thereof such as mometasone furoate i.e. (11 ⁇ ,16 ⁇ )-9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11- hydroxy-16-methylpregna-1 ,4-diene-3,20-dione, and pharmaceutical formulations thereof.
- Mometasone is an antiinflammatory corticosteroid, which is now used clinically in the treatment of respiratory disorders.
- a pharmaceutical formulation comprising formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
- a pharmaceutical formulation comprising formoterol fumarate and mometasone furoate (suitably as in the form of the monohydrate), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
- the above pharmaceutical formulations are suitable for administration by inhalation.
- formoterol includes two asymmetric centres, and mometasone contains several asymmetric centres.
- the present invention includes each isomer of formoterol either in substantially pure form or admixed in any proportions, particularly the (R,R)-isomer as well as each isomer of mometasone either in substantially pure form or admixed in any proportions.
- the enantiomers of formoterol have been described previously, for example, in WO 98/21175 and US5795564.
- physiologically functional derivative is meant a chemical derivative of formoterol or mometasone having the same physiological function as the free compound, for example, by being convertible in the body thereto.
- physiologically functional derivatives include esters.
- Suitable salts according to the invention include those formed with both organic and inorganic acids.
- Pharmaceutically acceptable acid addition salts include but are not limited to those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p- toluenesulphonic, benzenesulphonic, isethionic, and naphthalenecarboxylic, such as 1-hydroxy-2-naphthalenecarboxylic acids.
- esters of formoterol or mometasone may have a hydroxyl group converted to a C ⁇ _ 6 alkyl, aryl, aryl C ⁇ -6 alkyl, hetaryl (such as furanyl) or amino acid ester.
- formoterol and mometasone and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives have been described for use in the treatment of respiratory diseases. Therefore, formulations of formoterol and mometasone and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives have use in the prophylaxis and treatment of clinical conditions for which a selective ⁇ 2 -adrenoreceptor agonist and/or an antiinflammatory corticosteroid is indicated.
- Such conditions include diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease.
- COPD chronic obstructive pulmonary diseases
- the present invention provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective ⁇ 2 -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated, which comprises administration of a therapeutically effective amount of a combination of formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
- the present invention further provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective ⁇ 2 -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation comprising formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient.
- a pharmaceutical formulation comprising formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient.
- a method which comprises administration of a therapeutically effective amount of a pharmaceutical formulation comprising formoterol fumarate and mometasone furoate (suitably as the monohydrate), and a pharmaceutically acceptable carrier or excipient.
- a pharmaceutical formulation comprising formoterol fumarate and mometasone furoate (suitably as the monohydrate), and a pharmaceutically acceptable carrier or excipient.
- the present invention provides such methods for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
- COPD chronic obstructive pulmonary disease
- a pharmaceutical formulation comprising formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (suitably, formoterol fumarate) and mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (suitably, mometasone furoate optionally in the form of the monohydrate), and a pharmaceutically acceptable carrier or excipient for use in therapy, particularly for use in the prophylaxis or treatment of a clinical condition for which a selective ⁇ 2 -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated.
- the invention is concerned with the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
- COPD chronic obstructive pulmonary disease
- formoterol and mometasone, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the subject under treatment, and the particular disorder or disease being treated.
- formoterol fumarate is generally administered to adult humans by aerosol inhalation at a dose of 12mcg or 24mcg twice daily. While it is possible for the active ingredients of the combination to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation.
- the individual compounds of the combination are administered separately, they are generally each presented as a pharmaceutical formulation as described previously in the art.
- Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions.
- the inclusion of a package insert has been shown to improve patient compliance with the physician's instructions and, therefore, lead generally to more successful treatment. It will be understood that the administration of the combination of the invention by means of a single patient pack, or patient packs of each component compound, and containing a package insert instructing the patient to the correct use of the invention is a desirable additional feature of the invention.
- active ingredients means formoterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, preferably formoterol fumarate, and mometasone, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thefeof, preferably mometasone furoate.
- the pharmaceutical formulations which are suitable for inhalation according to the invention comprise the active ingredients in amounts such that each actuation provides therapeutically effective dose, for example, a dose of formoterol of 10mcg to 150mcg, preferably 24mcg and a dose of mometasone of 100mcg to 1.6mg, preferably 200mcg to 1mg, more preferably, 200mcg to
- the pharmaceutical formulations according to the invention may further include other therapeutic agents for example anti-inflammatory agents such as other corticosteroids (e.g. fluticasone propionate, beclomethasone dipropionate, budenoside, or triamcinolone acetonide), or NSAIDs (e.g.
- corticosteroids e.g. fluticasone propionate, beclomethasone dipropionate, budenoside, or triamcinolone acetonide
- NSAIDs e.g.
- ⁇ 2 -adrenoreceptor agonists such as salbutamol, salmeterol, fenoterol or terbutaline and salts thereof
- anticholinergic agents such as ipratropium, or tiotropium
- the formulations include those suitable for oral, parenteral (including subcutaneous, intraderrhal, intramuscular, intravenous and intraarticular), intranasal, inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredients into association with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations for inhalation include powder compositions which will preferably contain lactose, and spray compositions which may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1 ,1 ,1 ,2,3,3,3- heptafluoropropane, 1,1 ,1 ,2-tetrafluoroethane, carbon dioxide or other suitable gas.
- Suitable aerosol formulations include those described in EP 0372777 and WO93/11743.
- the active ingredients should be micronised so as to permit inhalation of substantially all of the active ingredients into the lungs upon administration of the aerosol formulation, thus the active ingredients will have a particle size of less than 100 microns, desirably less than 20 microns, and preferably in the range 1 to 10 microns, for example, 1 to 5 microns.
- Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
- Capsules and cartridges or for example gelatin, or blisters of for example laminated aluminium foil, for use in an inhaler or insuflator may be formulated containing a powder mix of the active ingredients and a suitable powder base such as lactose or starch.
- the active ingredients are suitably micronised so as to permit inhalation of substantially all of the active ingredients into the lungs upon administration of the dry powder formulation, thus the active ingredients will have a particle size of less than 100 microns, desirably less than 20 microns, and preferably in the range 1 to 10 microns.
- Solutions for inhalation by nebulation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.
- Preferred unit dosage formulations are those containing a pharmaceutically effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.
- a pharmaceutically effective dose as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.
- one actuation of the aerosol may deliver half of the therapeutically effective amount such that two actuations are necessary to deliver the therapeutically effective dose.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question.
- claimed formulations include bioequivalents as defined by the US Food and Drugs Agency.
- micronised active ingredients are weighed into an aluminium can, 1 ,1,1 ,2- tetrafluoroethane is then added from a vacuum flask and a metering valve is crimped into place.
- the active ingredients are micronised and bulk blended with the lactose in the proportions given above.
- the blend is filled into hard gelatin capsules or cartridges or in specifically constructed double foil blister packs to be administered by an inhaler such as a Rotahaler, Diskhaler, or Diskus inhaler (each of these being a Trademark of Glaxo Group Limited).
- Example 8 Aqueous nasal spray
- Example 9 Intranasal dry powder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention, qui a trait à des formulations pharmaceutiques renfermant une combinaison de formotérol et de mométasone, concerne également l'utilisation qui en faite en médecine, notamment dans la prophylaxie et le traitement de maladies respiratoires.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48541/01A AU4854101A (en) | 2000-04-18 | 2001-04-11 | Medical combinations comprising formoterol and mometasone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0009612.3A GB0009612D0 (en) | 2000-04-18 | 2000-04-18 | Therapeutic formulations |
GB0009612.3 | 2000-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001078744A1 true WO2001078744A1 (fr) | 2001-10-25 |
Family
ID=9890191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/001648 WO2001078744A1 (fr) | 2000-04-18 | 2001-04-11 | Produits composes a usage medical renfermant du formoterol et de la mometasone |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4854101A (fr) |
GB (1) | GB0009612D0 (fr) |
WO (1) | WO2001078744A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011711A2 (fr) * | 2000-08-04 | 2002-02-14 | Longwood Pharmaceutical Research, Inc. | Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire |
WO2003000241A2 (fr) * | 2001-06-23 | 2003-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouvelles compositions de medicament a base d'anticholinergiques, de corticosteroides et d'agents beta-mimetiques |
WO2003020253A2 (fr) * | 2001-08-28 | 2003-03-13 | Schering Corporation | Compositions pharmaceutiques pour le traitement de l'asthme |
EP1531866A1 (fr) * | 2002-08-29 | 2005-05-25 | Cipla Ltd. | Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides |
EP1574222A1 (fr) * | 2004-03-12 | 2005-09-14 | Cipla Ltd. | Procédé de stérilisation |
EP1712220A1 (fr) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Composition d'aérosol pharmaceutique |
WO2008102128A3 (fr) * | 2007-02-19 | 2009-01-08 | Cipla Ltd | Combinaisons pharmaceutiques |
US7758886B2 (en) | 2003-10-15 | 2010-07-20 | Pari Gmbh | Pharmaceutical aerosol composition |
WO2011093815A3 (fr) * | 2010-01-29 | 2011-10-20 | Mahmut Bilgic | Compositions pharmaceutiques comprenant du formotérol et du mométasone |
US8252268B2 (en) | 2002-04-05 | 2012-08-28 | 3M Innovative Properties Company | Formoterol and mometasone aerosol formulations |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4472393A (en) * | 1981-02-02 | 1984-09-18 | Schering Corporation | 3,20-Dioxo-1,4-pregnadiene-17α-ol 17-aromatic heterocycle carboxylates |
WO1998021175A1 (fr) * | 1996-11-11 | 1998-05-22 | Sepracor, Inc. | Procede de preparation d'isomeres de formoterol optiquement purs |
US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
WO1998041193A1 (fr) * | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation d'agglomerats de poudre |
WO2000051591A1 (fr) * | 1999-03-03 | 2000-09-08 | Novartis Ag | Combinaisons de formoterol et de furoate de mometasone destinees a l'asthme |
WO2000053187A1 (fr) * | 1999-03-09 | 2000-09-14 | Astrazeneca Ab | Nouvelle combinaison de formoterol et de mometasone dans une composition pharmaceutique permettant de traiter des troubles respiratoires tels que l'asthme, les rhinites et la broncho-pneumopathie chronique obstructive |
-
2000
- 2000-04-18 GB GBGB0009612.3A patent/GB0009612D0/en not_active Ceased
-
2001
- 2001-04-11 AU AU48541/01A patent/AU4854101A/en not_active Abandoned
- 2001-04-11 WO PCT/GB2001/001648 patent/WO2001078744A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4472393A (en) * | 1981-02-02 | 1984-09-18 | Schering Corporation | 3,20-Dioxo-1,4-pregnadiene-17α-ol 17-aromatic heterocycle carboxylates |
US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
WO1998021175A1 (fr) * | 1996-11-11 | 1998-05-22 | Sepracor, Inc. | Procede de preparation d'isomeres de formoterol optiquement purs |
WO1998041193A1 (fr) * | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation d'agglomerats de poudre |
WO2000051591A1 (fr) * | 1999-03-03 | 2000-09-08 | Novartis Ag | Combinaisons de formoterol et de furoate de mometasone destinees a l'asthme |
WO2000053187A1 (fr) * | 1999-03-09 | 2000-09-14 | Astrazeneca Ab | Nouvelle combinaison de formoterol et de mometasone dans une composition pharmaceutique permettant de traiter des troubles respiratoires tels que l'asthme, les rhinites et la broncho-pneumopathie chronique obstructive |
Non-Patent Citations (3)
Title |
---|
BARNES P J ET AL: "EFFICACY OF INHALED CORTICOSTEROIDS IN ASTHMA", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 102, no. 4, 1998, pages 531 - 538, XP000913470, ISSN: 0091-6749 * |
BOWLER S: "LONG ACTING BETA AGONISTS", AUSTRALIAN FAMILY PHYSICIAN, XX, XX, vol. 27, no. 12, December 1998 (1998-12-01), pages 1115,1117 - 1118, XP000973076 * |
O'CONNOR B J: "COMBINATION THERAPY", PULMONARY PHARMACOLOGY AND THERAPEUTICS, ACADEMIC PRESS, NEW YORK, NY, US, vol. 11, no. 5/6, 1998, pages 397 - 399, XP000911059, ISSN: 1094-5539 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011711A3 (fr) * | 2000-08-04 | 2003-02-27 | Longwood Pharmaceutical Res In | Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire |
WO2002011711A2 (fr) * | 2000-08-04 | 2002-02-14 | Longwood Pharmaceutical Research, Inc. | Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire |
WO2003000241A2 (fr) * | 2001-06-23 | 2003-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouvelles compositions de medicament a base d'anticholinergiques, de corticosteroides et d'agents beta-mimetiques |
WO2003000241A3 (fr) * | 2001-06-23 | 2003-12-11 | Boehringer Ingelheim Pharma | Nouvelles compositions de medicament a base d'anticholinergiques, de corticosteroides et d'agents beta-mimetiques |
EP2092935A1 (fr) * | 2001-08-28 | 2009-08-26 | Schering Corporation | Compositions pharmaceutiques pour le traitement de l'asthme |
WO2003020253A2 (fr) * | 2001-08-28 | 2003-03-13 | Schering Corporation | Compositions pharmaceutiques pour le traitement de l'asthme |
WO2003020253A3 (fr) * | 2001-08-28 | 2003-05-22 | Schering Corp | Compositions pharmaceutiques pour le traitement de l'asthme |
EP2319494A1 (fr) * | 2001-08-28 | 2011-05-11 | Schering Corporation | Compositions pharmaceutiques pour le traitement de l'asthme |
US8252268B2 (en) | 2002-04-05 | 2012-08-28 | 3M Innovative Properties Company | Formoterol and mometasone aerosol formulations |
EP1531866A1 (fr) * | 2002-08-29 | 2005-05-25 | Cipla Ltd. | Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides |
EP2322243A1 (fr) * | 2002-08-29 | 2011-05-18 | Cipla Ltd. | Produits pharmaceutiques et compositions à base de formotérol, de ciclésonide et de tiotropium |
US7758886B2 (en) | 2003-10-15 | 2010-07-20 | Pari Gmbh | Pharmaceutical aerosol composition |
US7892483B2 (en) | 2004-03-12 | 2011-02-22 | Cipla Limited | Sterilization process |
EP1574222A1 (fr) * | 2004-03-12 | 2005-09-14 | Cipla Ltd. | Procédé de stérilisation |
WO2006108556A3 (fr) * | 2005-04-15 | 2007-05-03 | Pari Gmbh | Composition pharmaceutique sous forme d'aerosol |
EP1712220A1 (fr) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Composition d'aérosol pharmaceutique |
WO2008102128A3 (fr) * | 2007-02-19 | 2009-01-08 | Cipla Ltd | Combinaisons pharmaceutiques |
WO2011093815A3 (fr) * | 2010-01-29 | 2011-10-20 | Mahmut Bilgic | Compositions pharmaceutiques comprenant du formotérol et du mométasone |
Also Published As
Publication number | Publication date |
---|---|
AU4854101A (en) | 2001-10-30 |
GB0009612D0 (en) | 2000-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030109510A1 (en) | Medical combinations comprising formoterol and budesonide | |
US20030113269A1 (en) | Medical combinations comprising tiotropium and fluticasone proprionate | |
US20030119859A1 (en) | Medical combinations comprising tiotropium and rofleponide | |
US20030119802A1 (en) | Medical combinations comprising tiotropium and budesonide | |
WO2001078745A1 (fr) | Produits composes a usage medical renfermant du formoterol et de la mometasone et du proprionate de fluticasone | |
US11090294B2 (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
US20030139383A1 (en) | Medical combinations comprising tiotropium and mometasone | |
US20040038953A1 (en) | Medical combination comprising salmeterol and budesonide | |
US20040009963A1 (en) | Use of salmeterol and fluticasone propionate combination | |
WO2001078744A1 (fr) | Produits composes a usage medical renfermant du formoterol et de la mometasone | |
US20050042171A1 (en) | Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma | |
US20030114537A1 (en) | Medical combinations comprising mometasone and salmeterol | |
AU2002334126A1 (en) | Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma | |
WO2001078738A1 (fr) | Compositions medicales comprenant du (r,r)-formoterol et du rofleponide | |
US20030096874A1 (en) | Respiratory compositions | |
US20040019025A1 (en) | Medical compositions comprising (r,r)-formoterol and rofleponide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |